Chih-Yi Liao
Hematology & Oncology · Chicago, ILNPI 1588958987
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $210,705 of the $316,894 with a category attached, or 66.5%. 16 manufacturers reported payments, led by Incyte Corporation at 31.6% of the total. 2025 is the largest year on record at $88,882, 2.8 times the $31,673 reported in 2019. Among hematology & oncology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $905.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$100K
- Exelixis Inc.$69K
- AstraZeneca$51K
- Boston Scientific$51K
- Ipsen Biopharmaceuticals, Inc$22K
- Eisai Inc.$8K
- plus $18K from 10 others
Across 317 payments — averaging $7729.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$770K
- AbbVie$395K
- Eli Lilly$223K
- Exelixis Inc.$177K
- Tersera Therapeutics LLC$163K
- AstraZeneca$161K
- plus $562K from 12 others
What the payments were for
- Consulting fees$61,85120%
- Speaking & faculty fees$210,70566%
- Travel & lodging$32,88410%
- Food & beverage$9,4543%
- Charitable contribution$2,0001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 92 | $100,197 |
| Exelixis Inc. | 83 | $68,559 |
| AstraZeneca | 38 | $50,941 |
| Boston Scientific | 65 | $50,501 |
| Ipsen Biopharmaceuticals, Inc | 32 | $21,577 |
| Eisai Inc. | 10 | $7,546 |
| Lexicon Pharmaceuticals, Inc. | 3 | $4,211 |
| Boehringer Ingelheim | 1 | $3,553 |
| Genentech USA, Inc. | 6 | $3,117 |
| Progenics Pharmaceuticals, Inc. | 4 | $2,252 |
| Taiho Oncology, Inc. | 3 | $2,116 |
| Lilly USA, LLC | 4 | $1,412 |
| Merck | 5 | $516 |
| Bayer | 2 | $235 |
| Medtronic | 1 | $109 |
| Seagen Inc. | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PEMAZYRE$84,331
- Cabometyx$66,818
- IMFINZI$43,362
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$34,961
- TheraSphere Y90 Glass Microspheres 10 GBq$11,182
- LENVIMA$7,431
- ONIVYDE$5,620
- SOMATULINE DEPOT$4,207
- Xermelo$4,173
- JAKAFI$3,880
- TECENTRIQ$2,974
- AZEDRA$2,226
- LYTGOBI$2,070
- KEYTRUDA$387
- Vitrakvi$235
- CYRAMZA$125
- WELIREG$125
- Emprint$109
How this compares
$316,894 in reported general payments places this provider in the 95th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WeliregBelzutifan | 12 | $350,241 |
| LenvimaLenvatinib Mesylate | 11 | $235,245 |
| Everolimus | 12 | $47,034 |
| Dexamethasone | 20 | $488 |
| Prochlorperazine Maleate | 30 | $430 |
| Ondansetron Hcl | 23 | $398 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckWelireg | $516 | $350,24112 claims |
| Eisai Inc.Lenvima | $7,546 | $235,24511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
- Reem KarmaliChicago$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.